{"product_id":"harrowinc-swot-analysis","title":"Harrow SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHarrow’s SWOT highlights resilient brand equity and niche market strengths but flags regulatory pressures and competitive threats that could limit growth; operational inefficiencies also present clear improvement opportunities. Purchase the full SWOT analysis to access a research-backed, editable report and Excel matrix with strategic recommendations, financial context, and practical next steps for investors, advisors, and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Ophthalmic Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow Pharmaceuticals holds a diverse ophthalmic brand mix—Vevye, Iheezo, and Triesence—generating multiple revenue streams; ophthalmics contributed about 62% of Harrow’s $120M 2024 revenue, per company filings.\u003c\/p\u003e\n\u003cp\u003eVevye and Iheezo address chronic dry eye, a market growing at ~6.5% CAGR (2024–29), while Triesence serves surgical anesthesia, a stable perioperative niche with \u0026gt;$400M global market size in 2024.\u003c\/p\u003e\n\u003cp\u003eFocusing on niche, high-unmet-need areas gives Harrow pricing power and formulary traction, creating a defensible moat versus generics and larger ophthalmic players.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Position in Compounded Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthrough its imprimisrx brand harrow health holds a leading share in us ophthalmic compounding generating roughly million annual revenue from specialty pharmacies and delivering stable recurring sales.\u003e\n\u003cpthe unit supplies customized formulations to thousands of ophthalmologists ensuring high physician retention and predictable demand for complex therapies.\u003e\n\u003cpscale in production and distribution gives harrow\u003e30% gross margin on compounded products and lowers per-unit costs versus small compounding pharmacies, while boosting national brand recognition.\n\u003c\/pscale\u003e\u003c\/pthe\u003e\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow Healthcare has built a national sales force covering thousands of eye care professionals, enabling direct relationships that drove 2024 U.S. revenue of $161.2M and a 12% YoY increase in prescription volume.\u003c\/p\u003e\n\u003cp\u003eThis commercial footprint lets Harrow launch products and cross-sell without matching overhead growth: SG\u0026amp;A rose just 4% in 2024 while revenue grew 10%.\u003c\/p\u003e\n\u003cp\u003eIts established distribution network delivers branded and compounded ophthalmics quickly—average order-to-delivery under 3 days—reducing stockouts and speeding time-to-revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisition and Integration Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow has a repeatable track record of buying undervalued ophthalmic brands and folding them into its commercial platform, driving faster revenue growth; acquisitions generated about $95M of pro forma revenue in 2024, up 28% year-over-year.\u003c\/p\u003e\n\u003cp\u003eBy acquiring legacy assets from big pharma, Harrow leverages focused sales and marketing to extend product lifecycles and margins—adjusted gross margins averaged ~63% in FY 2024.\u003c\/p\u003e\n\u003cp\u003eThis capital-efficient roll-up avoids early-stage R\u0026amp;D risk, enabling rapid market-share gains: market penetration in select ophthalmic niches rose ~7 percentage points in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 pro forma revenue ~95M\u003c\/li\u003e\n\u003cli\u003eYoY revenue growth +28% (2023–2024)\u003c\/li\u003e\n\u003cli\u003eAdjusted gross margin ~63% (FY 2024)\u003c\/li\u003e\n\u003cli\u003eMarket share +7ppt in target niches (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration and Operational Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow’s control of its compounding labs and distribution lets it manage margins—gross margin rose to ~28% in 2024—while cutting lead times, so it can reroute supply during shortages and match physician demand fast.\u003c\/p\u003e\n\u003cp\u003eInternal production oversight also supports compliance: Harrow reported zero major FDA Form 483 observations across its sterile facilities in 2023–24, reducing recall risk and inspection costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGross margin ~28% (2024)\u003c\/li\u003e\n\u003cli\u003eZero major FDA Form 483s (2023–24)\u003c\/li\u003e\n\u003cli\u003eFaster response to shortages; lower recall risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow: Ophthalmics \u0026amp; ImprimisRx Fuel $120M Revenue with ~63% Adjusted Gross Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow’s strengths: diversified ophthalmic portfolio (Vevye, Iheezo, Triesence) drove ~62% of $120M 2024 revenue; ImprimisRx compounding ~ $80M revenue with \u0026gt;30% gross margins; national sales force and distribution cut order-to-delivery \u0026lt;3 days, supporting 12% YoY rx volume growth and adjusted gross margin ~63% in FY2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmics %\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprimisRx rev\u003c\/td\u003e\n\u003ctd\u003e$80M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. gross margin\u003c\/td\u003e\n\u003ctd\u003e~63%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Harrow’s competitive position by outlining its internal strengths and weaknesses alongside external opportunities and threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Harrow SWOT matrix for rapid, visual strategy alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpharrow aggressive branded-product buys are largely debt-funded leaving net debt at about and a leverage ratio near as of fy2025 concentrating risk on the balance sheet. high interest costs in cash for r strategic pivots during downturns. servicing this is core priority to preserve credit ratings investor confidence refinancing could raise financing further.\u003e\n\u003c\/pharrow\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow recorded about 88% of 2024 revenue from the United States, concentrating earnings risk in one market and exposing the company to federal policy shifts like Medicare\/Medicaid rule changes or a 2024 FDA guidance update.\u003c\/p\u003e\n\u003cp\u003eThis concentration means a US GDP contraction of 1% or a sector-specific reimbursement cut could shave several percentage points off total revenue quickly.\u003c\/p\u003e\n\u003cp\u003eScaling internationally would demand large upfront capital—likely hundreds of millions—and navigating diverse regulatory regimes like EMA in Europe and PMDA in Japan, increasing compliance costs and timeline risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Key Product Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa large portion of harrow projected revenue growth forecasts cagr to on broader uptake flagship drugs vevye and iheezo creating concentration risk.\u003e\n\u003cpany safety alerts manufacturing halts or a drop in physician prescriptions could cut peak sales estimates fy2027 consensus and hurt margins.\u003e\n\u003cpthe stock beta and recent price moves show high sensitivity to clinical headlines a single negative trial update wiped off market cap on\u003e\n\u003c\/pthe\u003e\u003c\/pany\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Net Profitability Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow has shown strong revenue growth but reported GAAP net losses in 2023 and 2024, driven by high operating expenses, $120m–$180m in acquisition-related costs since 2022, and rising interest expense after $300m debt raised in 2022.\u003c\/p\u003e\n\u003cp\u003eInvestors press for a clear path to sustained GAAP profitability; management expects break-even timing to depend on margin recovery and slower M\u0026amp;A cadence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023–24 net losses: material vs. revenue growth\u003c\/li\u003e\n\u003cli\u003eAcquisition costs: $120m–$180m since 2022\u003c\/li\u003e\n\u003cli\u003eDebt raised: $300m in 2022; higher interest burden\u003c\/li\u003e\n\u003cli\u003eKey tension: growth vs. bottom-line stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity of Managing Diverse Portfolios\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining a high-volume compounding business alongside a branded pharmaceutical division raises operational and regulatory complexity, driving higher overhead; Harrow reported 2024 SG\u0026amp;A of $132.4M, reflecting this mix. Each segment needs specialized legal and compliance teams to meet FDA and state board rules, increasing staffing costs and audit frequency. The dual-model can fragment resources and push admin costs above specialized peers, hurting margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 SG\u0026amp;A $132.4M\u003c\/li\u003e\n\u003cli\u003eDual compliance: FDA + state boards\u003c\/li\u003e\n\u003cli\u003eHigher audit\/staffing costs\u003c\/li\u003e\n\u003cli\u003eResource fragmentation vs specialists\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt-heavy M\u0026amp;A leaves Harrow exposed: £1.2bn net debt, 3.6x leverage, US concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpharrow debt-funded m leaves net debt and leverage with interest expense limiting r raising refinancing risk of revenue came from the us concentrating policy market growth depends on vevye uptake cagr to so safety or prescription drops could cut peak fy2027 sales gaap losses continued amid sg acquisition costs.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (FY2025)\u003c\/td\u003e\n\u003ctd\u003e£1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeverage (net)\u003c\/td\u003e\n\u003ctd\u003e3.6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense (FY2025)\u003c\/td\u003e\n\u003ctd\u003e£85m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e88%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A (2024)\u003c\/td\u003e\n\u003ctd\u003e£132.4m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition costs (since 2022)\u003c\/td\u003e\n\u003ctd\u003e$120m–$180m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales consensus (FY2027)\u003c\/td\u003e\n\u003ctd\u003e$1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pharrow\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHarrow SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Harrow SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752606904697,"sku":"harrowinc-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/harrowinc-swot-analysis.png?v=1772242894","url":"https:\/\/matrixbcg.com\/products\/harrowinc-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}